Immunoparalysis Program
Acquired Immune Deficiency in Critically Ill Patients (e.g., Sepsis)
Pre-clinicalGroundbreaking approach in development; first-in-class potential.
Key Facts
Indication
Acquired Immune Deficiency in Critically Ill Patients (e.g., Sepsis)
Phase
Pre-clinical
Status
Groundbreaking approach in development; first-in-class potential.
Company
About Combioxin
Combioxin is dedicated to revolutionizing the treatment of severe infections and immune dysfunction in intensive care. Its core technology uses proprietary engineered liposomes to capture and neutralize bacterial toxins, offering a novel mechanism against both Gram-positive and Gram-negative pathogens. The company has achieved significant regulatory milestones for CAL02, initiated a global Phase 2b study, and secured a worldwide out-licensing agreement with Eagle Pharmaceuticals, positioning it to address a critical unmet medical need with high mortality and cost.
View full company profile